Glutamate receptor targets GRIA1 (rank 13, score 16.28) and GRIN2A (rank 15, score 15.33) represent particularly promising symptomatic treatment opportunities, as both targets are already addressed by FDA-approved memantine and other glutamate receptor modulators currently used in Alzheimer’s disease management. The gene discussed is GRIA1; the disease is early-onset autosomal dominant Alzheimer disease.